Comparative Immunogenicities of Chikungunya Vaccines Propagated in Monkey Kidney Monolayers and Chick Embryo Suspension Cultures

White, A. Clinton; Berman, Sanford; Lowenthal, Joseph P.

doi:10.1128/aem.23.5.951-952.1972

Cited by 23 publications

(10 citation statements)

References 4 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No vaccine against chikungunya is currently available. The first attempts to develop an inactivated vaccine were reported at the end of the 1960s and involved detergent treatment of virus (White et al, 1972). Unfortunately, these formalin-killed vaccines which showed promise appeared to be moderately immunogenic and limited to short time effects in a clinical trial (Harrison et al, 1971).…”

Section: Vaccinesmentioning

confidence: 99%

Chikungunya fever: Epidemiology, clinical syndrome, pathogenesis and therapy

et al. 2013

View full text Add to dashboard Cite

Chikungunya virus (CHIKV) is the aetiological agent of the mosquito-borne disease chikungunya fever, a debilitating arthritic disease that, during the past 7years, has caused immeasurable morbidity and some mortality in humans, including newborn babies, following its emergence and dispersal out of Africa to the Indian Ocean islands and Asia. Since the first reports of its existence in Africa in the 1950s, more than 1500 scientific publications on the different aspects of the disease and its causative agent have been produced. Analysis of these publications shows that, following a number of studies in the 1960s and 1970s, and in the absence of autochthonous cases in developed countries, the interest of the scientific community remained low. However, in 2005 chikungunya fever unexpectedly re-emerged in the form of devastating epidemics in and around the Indian Ocean. These outbreaks were associated with mutations in the viral genome that facilitated the replication of the virus in Aedes albopictus mosquitoes. Since then, nearly 1000 publications on chikungunya fever have been referenced in the PubMed database. This article provides a comprehensive review of chikungunya fever and CHIKV, including clinical data, epidemiological reports, therapeutic aspects and data relating to animal models for in vivo laboratory studies. It includes Supplementary Tables of all WHO outbreak bulletins, ProMED Mail alerts, viral sequences available on GenBank, and PubMed reports of clinical cases and seroprevalence studies.

show abstract

Section: Vaccinesmentioning

confidence: 99%

Chikungunya fever: Epidemiology, clinical syndrome, pathogenesis and therapy

et al. 2013

View full text Add to dashboard Cite

show abstract

“…challenge. Curiously, a separate study indicated that the CE preparation generated up to 5 times more antibody than the GMKC preparation (25). It was subsequently determined that the titer of the virus prior to formalin inactivation was critical for a potent immune response, with a highly concentrated product being necessary.…”

Section: History Of Chikv Vaccine Developmentmentioning

confidence: 99%

Vaccine and Therapeutic Options To Control Chikungunya Virus

2018

View full text Add to dashboard Cite

Beginning in 2004, chikungunya virus (CHIKV) went from an endemic pathogen limited to Africa and Asia that caused periodic outbreaks to a global pathogen. Given that outbreaks caused by CHIKV have continued and expanded, serious consideration must be given to identifying potential options for vaccines and therapeutics. Currently, there are no licensed products in this realm, and control relies completely on the use of personal protective measures and integrated vector control, which are only minimally effective. Therefore, it is prudent to urgently examine further possibilities for control. Vaccines have been shown to be highly effective against vector-borne diseases. However, as CHIKV is known to rapidly spread and generate high attack rates, therapeutics would also be highly valuable. Several candidates are currently being developed; this review describes the multiple options under consideration for future development and assesses their relative advantages and disadvantages.

show abstract

“…Vaccine – The first attempts to develop inactivated and attenuated vaccines against CHIKV resulted in products with low immunogenicity and adverse effects such as arthralgia ( Harrison et al, 1971 , White et al, 1972 ). Although some options are being evaluated, such as the use of recombinant antigens, viral-like particles, chimeric alphaviruses, electroporated DNA, and CHIKV attenuated by large-scale codon re-encoding, no vaccines are currently available ( Thiberville et al, 2013 ).…”

Section: Treatmentmentioning

confidence: 99%

Chikungunya virus: clinical aspects and treatment - A Review

Cunha

Trinta

2017

Mem. Inst. Oswaldo Cruz

158

129

View full text Add to dashboard Cite

Chikungunya is a severe and debilitating disease. Currently, Brazil is experiencing an epidemic caused by three arboviruses, which has changed the way health professionals have diagnosed and treated infected patients. The difficulty of diagnosis and the lack of a protocol for patient treatment, which fits Brazilian health system models, have made it difficult to manage this disease. It is necessary to implement a multidisciplinary network of patient care, in which primary care units play the main role. This review aims to present current information regarding the clinical aspects and treatment of Chikungunya virus infection.

show abstract

Comparative Immunogenicities of Chikungunya Vaccines Propagated in Monkey Kidney Monolayers and Chick Embryo Suspension Cultures

Cited by 23 publications

References 4 publications

Chikungunya fever: Epidemiology, clinical syndrome, pathogenesis and therapy

Chikungunya fever: Epidemiology, clinical syndrome, pathogenesis and therapy

Vaccine and Therapeutic Options To Control Chikungunya Virus

Chikungunya virus: clinical aspects and treatment - A Review

Contact Info

Product

Resources

About